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Chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) belongs to the steroid/thyroid hormone
receptor superfamily. Extensive evidence has indicated that COUP-TFII plays a critical and indispensable role in
cell-fate specification, organogenesis, angiogenesis, and metabolism as well as in a variety of diseases. Recent
studies obtained from genetically engineered mouse models (GEM) and patient specimen analysis indicate that
COUP-TFII is also important for tumor progression and metastasis. In this article, we will comprehensively review
the oncogenic roles of COUP-TFII within the tumor microenvironment and tumor cells and delineate the mechanism
by which COUP-TFII contributes to tumorigenesis. The applicability of current data to our understanding of the role of
COUP-TFII in cancer and the potential therapeutic implications will also be discussed.The nuclear receptor (NR) superfamily of ligand-activated
receptors exhibit a common modular structure and play
essential roles, not only in maintaining cellular homeosta-
sis, but also in various disease processes including cancer
and metabolism disorder [1,2]. Chicken ovalbumin up-
stream promoter transcription factor II (COUP-TFII, also
named as NR2F2), a member of the steroid/thyroid hor-
mone receptor superfamily, was originally identified to
be a transcriptional factor regulating the expression of
the chicken ovalbumin gene in chicken oviducts [3].
COUP-TFII possesses the classic domain structure of nu-
clear receptors. Specifically, it encompasses two highly
conserved motifs: 1) a DNA-binding domain (DBD) con-
taining two zinc-fingers; and 2) a putative ligand-binding
domain (LBD) (Figure 1A) [4]. COUP-TFII can activate or
repress gene expression in both a tissue-specific and gene-
specific manner through mechanisms involving direct
binding to DNA response elements or binding to other
transcription factors. Through binding to 5’-AGGTCA-3’
direct repeats (DR) with variable spacing, COUP-TFII re-
presses gene expression through the recruitment of CoR
(corepressor) (Figure 1B) [4]. Alternatively, COUP-TFII
can also bind to Sp1 sites to cooperatively activate gene* Correspondence: stsai@bcm.edu; mtsai@bcm.edu
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unless otherwise stated.expression such as Angiopietin-1 (Ang-1) and Neuropilin
2 (Nrp2) (Figure 1B) [5,6].
In the past decades, great insights have been obtained
into the physiological function of COUP-TFII during em-
bryonic and postnatal development. Using genetically engi-
neered mouse models (GEM) together with molecular
analysis, it has been well documented that COUP-TFII
serves as one of the master regulators to control develop-
mental programs, including organogenesis, angiogenesis,
cardiovascular development, reproduction, neuronal devel-
opment and metabolic homeostasis [7-15]. Mechanistic in-
vestigations uncover that COUP-TFII exerts its function
through modulation of cell proliferation, migration, sur-
vival, fate determination and differentiation in a context
dependent manner. Aside from its critical roles in physio-
logical process [10], recent studies also reveal that COUP-
TFII plays important roles in pathological processes such as
cancer [5,6,16-19], congenital diaphragmatic hernia (CDH)
[12] and diabetes [11]. Since the function of COUP-TFII in
developmental processes has been extensively reviewed re-
cently [20], here we will focus on its role in tumorigenesis
as well as its underlying mechanism, and discuss potential
therapeutic implications for cancer intervention.
Role of COUP-TFII in the tumor microenvironment
COUP-TFII is highly expressed in the mesenchymal cell
compartment during embryogenesis, whereas its expres-
sion is relatively low in the adult epithelium [10]. Thus,
it is not surprising that ablation of COUP-TFII in adults. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
















































Figure 1 Schematic structure COUP-TFII and known mechanism of its transcriptional regulation. A) Schematic structure of human
COUP-TFII proteins. DNA-binding domain (DBD); ligand-binding domain (LBD) B) COUP-TFII binds to 5′-AGGTCA-3′ motif palindromes (DR site),
either directly (homodimer) or indirectly, through heterodimer formation with other proteins (e.g. RXRs) to regulate downstream target gene
expression. In addition, COUP-TFII can also bind to Sp1 sites through interaction with Sp1 to cooperatively activate gene expression.
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COUP-TFII is not important for maintenance function,
but it is essential for regeneration or dedifferentiation
processes, which often occur under pathological condi-
tions in adults. Given the fact that disease malignance
often shares similar mechanisms as developmental pro-
cesses, the knowledge gained from studying the COUP-
TFII knockout mice in the past has a major impact
on the understanding of the disease processes. At em-
bryonic day 9.5 (E9.5), COUP-TFII null mutants display
a severe defect in angiogenesis as evidenced by the ob-
servations that the primitive capillary plexus fails to
undergo remodeling to generate large and small micro-
capillaries as well as the inability of the capillary to in-
vade into areas lacking blood vessels [15]. Likewise,
depletion of COUP-TFII in the postnatal stage signifi-
cantly compromised blood vessel formation by using ret-
ina angiogenesis as a neo-angiogenesis model (Figure 2).
As we all know, cancer cells often hijack a variety of nor-
mal cellular processes to enable survival and expansion




Figure 2 Roles of COUP-TFII in retinal vascular development. Analysis
vessels from P8 mice. Animals were treated with tamoxifen at E18.5 to indu
positive density and number of vessel branch points are graphed as mean
of the vascular network were substantially reduced in the mutant retina in
Rosa26CreERT2/+, COUP-TFIIFlox/Flox.intriguing possibility that COUP-TFII might be critical for
tumor angiogenesis, which often shares similar genetic
pathways with neo-angiogenesis. In agreement with this
notion, our lab has identified that COUP-TFII serves as
one of the major angiogenic regulators within the tumor
microenvironment to promote tumor angiogenesis in a
spontaneous breast cancer model (MMTV-PyMT) and
pancreatic cancer model (RIP1-Tag2) [6,10,18,19].
It is well accepted that tumor progression, invasion,
and metastasis requires blood vessels and lymphatic ves-
sels to provide oxygen and nutrients to sustain tumor
growth [21]. In COUP-TFII mutant mice, vessel growth
is dampened, rendering tumor cells lacking blood sup-
ply and undergoing apoptosis or necrosis [6,19]. As a
consequence, tumor progression is inhibited in COUP-
TFII depleted mice. More importantly, impeding the
paths for tumors to escape from the primary sites into
the circulating system, tumor metastasis is also inhibited
with the loss of COUP-TFII. Further mechanistic investi-
gations uncover that COUP-TFII modulates multiple
angiogenic signals (VEGF/VEGFR-2, Angpoietin/Tie2,of changes in retinal microvasculature by Isolectin B4 staining of retinal
ce COUP-TFII deletion at the postnatal stage. Relative Isolectin B4-
(±SEM) (N = 10) * P < 0.05. We showed that the complexity and density
comparison with the control retina. F/F: COUP-TFIIFlox/Flox; Cre/+, F/F:
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angiogenesis [6,18,19]. In pericytes, COUP-TFII directly
regulates Ang-1 expression. Ang-1/Tie2 signaling serves
as a paracrine signal for vascular remodeling and matur-
ation. In addition, COUP-TFII plays a cell autonomous
role within endothelial cells to promote vessel sprouting.
Depletion of COUP-TFII significantly inhibits endothe-
lial cell sprouting partly through transcriptional dere-
pression of vascular endothelial growth factor receptor 1
(VEGFR-1). Given the fact that the soluble and the
membrane bound VEGFR-1 potently sequester VEGF
binding to the vascular endothelial growth factor recep-
tor 2 (VEGFR-2), VEGF/VEGR-2 signaling [21], a major
driving force for tumor angiogenesis, is inhibited upon
COUP-TFII depletion. The functional relevance between
COUP-TFII and VEGFR-2 signaling is further substanti-
ated by rescue experiments in which neutralization of
VEGFR-1 overexpression caused by COUP-TFII ablation
partially restores vessel sprouting concomitant with the
hyperactivation of VEGF/VEGR-2 signaling. Moreover,
we also demonstrated that COUP-TFII directly controls
E2F1 expression and represses Notch signaling in endo-
thelial cells to modulate cell proliferation and migration
[18]. Taken together, the above results indicate that
COUP-TFII directly regulates the transcription of three
key genes, E2F1 and VEGFR-1 in endothelial cells, and
Ang-1 in pericytes, to coordinate endothelial cell prolif-
eration, sprouting, and vascular remodeling [6,18,19].
Interestingly, COUP-TFII is expressed not only in the
venous endothelial cells [12], but also in the lymphatic
endothelial cells (LECs) [5]. Lin et al. identified that
COUP-TFII controls sprouting lymphangiogenesis through
direct transcriptional regulation of Nrp2, a co-receptor for
VEGF-C and thereby modulates the VEGF-C/VEGFR-3
signaling pathway in the lymphatic system [5]. As expected,
inactivation of COUP-TFII in the tumor microenvi-
ronment substantially suppresses tumor-induced neo-
lymphangiogenesis. Given the facts that there is limited
success for anti-angiogenic therapy (Bevacizumab and
Sunitinib) in patients and COUP-TFII potently targets
multiple angiogenic and lymphangiogenic pathways within
the tumor microenvironment, these studies prompted the
rational basis that COUP-TFII might represent a potential
therapeutic target and inhibition of COUP-TFII may offer
an efficacious approach for anti-angiogenic intervention.
One important question that remains to be defined is
whether COUP-TFII is involved in tip and stalk cell spe-
cification during vessel sprouting. During angiogenesis,
reciprocal inhibition between Notch and VEGFR-2 sig-
naling has been shown to be critical for the tip and stalk
cell specification [22-24]. We have shown that COUP-
TFII activates VEGFR-2 signaling via direct repression
of VEGFR-1 expression [19]. In addition, COUP-TFII
antagonizes Notch signaling through direct regulation ofplayers at multiple steps of the Notch cascade including
Foxc1, Np-1, and Hey2 [18]. Thus, it is reasonable to
speculate that COUP-TFII is preferably expressed in tip
cells to ensure the inactivation of Notch signaling and acti-
vation of VEGFR-2 signaling during the sprouting process
(Figure 3). On the other hand, Notch signaling and
VEGFR-1 expression will be expected to be up-regulated
in stalk cells due to the absence of COUP-TFII. Thus,
these complicated hierarchies of signaling interactions are
coordinated, and the orchestration among COUP-TFII,
VEGF/VEGFR-2 signaling, and Notch signaling remains to
be further elucidated, which might provide new insights
for the underling mechanism of tumor angiogenesis and
identify new targets for anti-angiogenic therapy.
The cell autonomous role of COUP-TFII in tumor cells
COUP-TFII in prostate cancer
In contrast to the expression profile observed in normal
tissue, aberrant COUP-TFII expression has been fre-
quently reported in different types of human tumors in-
cluding breast cancer [25,26], pancreatic adenocarcinoma
[27], colorectal cancer [28], ovarian cancer [29-31] and
prostate carcinomas [16]. Therefore, the important ques-
tion is whether COUP-TFII also plays an important role in
tumor cells to modulate tumor progression and metasta-
sis. To address this issue, COUP-TFII expression in more
than 400 prostate cancer patient specimens has been eval-
uated. The results indicate that the expression of COUP-
TFII is significantly elevated in prostate tumors, and
further increased in metastatic prostate cancer patients
[16]. Approximately 60% of all tumors exhibit intermedi-
ate to intense staining, whereas only 5% of the non-tumor
tissue stained positive for COUP-TFII. More importantly,
COUP-TFII expression in prostate tumor cells correlates
with increased risk of tumor recurrence and decreased
survival after prostatectomy, suggesting that COUP-TFII
is a potential biomarker for aggressive PCa diagnosis. Fur-
thermore, the results that COUP-TFII-deficiency in asso-
ciation with PTEN loss profoundly impacts prostate
tumorigenesis, affecting the size, progression, and severity
of lesions, indicating that COUP-TFII plays a causal role
in disease progression. More importantly, prostate-specific
overexpression of COUP-TFII cooperates with PTEN loss
to produce an invasive cancer and promotes the metasta-
sis of tumor cells to distant tissues. Taken together, these
results indicate an oncogenic role of COUP-TFII in driv-
ing the indolent tumor to become a metastatic-prone
prostate cancer.
Mechanistic investigations further reveal that COUP-
TFII associates with Smad4 and inhibits its transcriptional
activity, and consequently counteracts the TGF-β signaling
induced growth barrier for PTEN null indolent tumors
[16]. The functional antagonism between COUP-TFII and

















Figure 3 Potential model for COUP-TFII function in tip and stalk cell specification during angiogenesis. COUP-TFII is preferably expressed
in tip cells to ensure the inactivation of Notch signaling and activation of VEGFR-2 signaling during the sprout process. In stalk cells, Notch
signaling and VEGFR-1 expression will be up-regulated due to the absence of COUP-TFII.
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mice lacking COUP-TFII, and overexpression of COUP-
TFII does not exacerbate tumor malignance further in the
absence of Smad4. Multivariate analysis in patients further
substantiates the functional relevance of COUP-TFII and
TGF-β signaling in prostate cancer. The COUP-TFII
signature carries an independent predictive value to fur-
ther enhance the prognostic accuracy of four genes’ pre-
diction, including PTEN, Smad4, p21 and CyclinD1.
Taken together, these results demonstrate that COUP-
TFII-mediated inhibition of TGF-β signaling is important
for the PTEN-null prostate to develop into fully pene-
trated prostate cancer (Figure 4).
Having established that COUP-TFII serves as a critical
regulator to counteract the TGF-β-induced growth bar-
rier, the detailed mechanism remains to be further dis-
sected. These phenotypes rely in part on inhibition of
TGF-β signaling via physical interaction with Smad4.
As a consequence, the downstream target genes of
TGF-β relevant to growth response, such as p21, p15
and Cyclin D1, are deregulated, which will lead to cell
senescence and inhibition of cell growth in COUP-TFII
deficient mice (Figure 4). COUP-TFII sequesters Smad4
binding to target genes, which will be one of the mecha-
nisms for COUP-TFII inhibitory effects on TGF-β sig-
naling. However, as a transcription factor, COUP-TFII
might also recruit co-repressors to the complex or dis-
rupt the bindings of Smads to the co-activators such asCBP/P300. In addition to TGF-β signaling, COUP-TFII
also induced a specific set of genes for cell growth and
metastasis to fully establish malignant phenotypes. Ana-
lyses of gene expression arrays indicate that many cell
growth and metastasis related genes, including E2F1,
Cyclin B, SRC-3, FoxO1, FoxM1 and MMPs, are dysreg-
ulated upon COUP-TFII depletion. We have identified
that COUP-TFII can directly control E2F1 transcription
in a Sp1 dependent manner. E2F1 is known to be a
major regulator for G1/S phase transition [32]. Thus,
the mechanism that COUP-TFII promotes tumor pro-
gression and metastasis is not limited to its modulation
of anti-proliferative effects of TGF-β signaling.
TGF-β has biphasic effects during tumorigenesis,
acting early as a tumor suppressor, but later stimulating
cancer progression through its effect on the tumor cells
and their microenvironment [33]. It seems elusive that
overexpression of COUP-TFII promotes cancer metas-
tasis and at the same time inhibits TGF-β signaling.
However, we believe that tumors bearing high levels
of COUP-TFII will be resistant to growth inhibitory
effects caused by TGF-β signaling and will enable
the tumor cells to accumulate mutations and gain
metastatic potential. Since TGF-β signaling is hypoacti-
vated upon COUP-TFII overexpression, COUP-TFII
might modulate other pathways or regulators to pro-
mote tumor metastasis, which has yet to be further
elucidated.
Figure 4 Working model for COUP-TFII function in prostate tumorigenesis. PTEN inactivation results in an increase of COUP-TFII expression
in prostate cancer cells, which will consequently promote tumor growth through the regulation of cell cycle or growth related genes such as
E2F1, Cyclin A, Cyclin B and etc. In addition, further increase in COUP-TFII expression in prostate cancer constrains the TGF-β-dependent growth
barrier through direct association with Smad4, thereby downregulating p21 expression and enhancing Cyclin D1 expression. In summary,
COUP-TFII serves as an important regulator to control PTEN-mediated prostate tumorigenesis and renders the indolent tumors to acquire
metastatic potential through destruction of the TGF-β-dependent growth barrier.
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It is reasonable to speculate that COUP-TFII might be in-
volved in other cancer types in addition to prostate cancer.
Indeed, COUP-TFII is among a limited group of NRs that
are prognostic for breast cancer classification and histo-
logic grade. In 119 human breast cancer patients, fifty-
nine percent of the specimens are immunohistochemically
positive for COUP-TFII, and COUP-TFII expression level
positively correlates with a poor clinical stage, lymph node
status, histological grade and estrogen receptor alpha sta-
tus [25]. However, in contrast to this finding, Litchfield
et al. reported that COUP-TFII expression is negatively as-
sociated with clinical outcome and disease progression
[26]. Though COUP-TFII expression is higher in ERα +
breast cancer samples, its expression is significantly lower
in metastatic samples [26]. In addition, COUP-TFII is re-
duced in tamoxifen-resistant human breast cancer cells,
and ectopic expression of COUP-TFII renders the cells to
be tamoxifen sensitive [34]. Thus, the prognostic signifi-
cance of COUP-TFII varies between studies for breast
cancer, and whether this is due to different subsets of pa-
tients needs to be clarified.
In ovarian cancer, it is generally believed that COUP-
TFII expression is downregulated in comparison withnormal counterparts [29-31]. However, one needs to
take into account that COUP-TFII is highly expressed in
the stroma of a healthy ovary with little or no expression
in the epithelium. Thus, downregulation of COUP-TFII
in ovarian cancer based on microarray data may only re-
flect the composition changes between tumor and nor-
mal tissue, since tissue compartmental ratios (epithelial
versus stromal) have been significantly altered once a
tumor is formed. Using tissue microarray assay, recent
studies partially resolved this puzzle [30]. Interestingly,
they found that ectopic epithelial expression of COUP-
TFII is frequently observed in ovarian cancer patients.
The frequency of COUP-TFII staining in the epithelium
of metastatic ovarian cancers is significantly higher than
the levels observed in the indolent ones, and tumors
having higher COUP-TFII expression in the epithelium
is associated with a trend toward greater likelihood of
disease recurrence [30], supporting an oncogenic role of
COUP-TFII in ovarian cancer at least in the epithelium
compartment. In pancreatic adenocarcinoma, COUP-
TFII is expressed in 69% of tested primary samples and
correlates with the N1 and M1 status and clinical stage;
Kaplan-Meier and Cox regression analysis show that it
may be an independent prognostic factor of a worse
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the cell growth and invasiveness. In colon cancer, COUP-
TFII is observed in more than 57% of tumors from colon
cancer patients, and there was minimal expression in nor-
mal colonic mucosa; expression of the receptor correlated
with increased rates of disease-free survival. Taken to-
gether, the prognostic significance of COUP-TFII varies
between studies and cancer types, and the precise roles of
COUP-TFII in cancer progression and metastasis are still
elusive. These differences reported in literature may be
due to the intrinsic differences among various cancer types
and COUP-TFII may exert its functions in a context
dependent manner.
Concluding remarks
This review has highlighted a critical role of transcrip-
tion factor COUP-TFII in tumor progression and metas-
tasis. In prostate tumor cells, COUP-TFII counteracts
the TGF-β-dependent growth barrier to drive prostate
tumor growth and metastasis (Figure 4) [16]. In addition,
COUP-TFII in the tumor microenvironment promotes
angiogenesis to facilitate growth and metastasis of breast
and pancreatic tumors [6,18,19]. Since nuclear receptors,
whose activity can be regulated by small molecular com-
pounds [1], are ideal targets for drug discovery [35],
COUP-TFII might represent as an excellent and “drug-
gable” target for cancer intervention. Indeed, X-ray crystal-
lography indicates that COUP-TFII contains a ligand-
binding pocket whose activity can be regulated by small
diffusible ligands [36]. In accordance with this notion, 9-
cis- and all-trans retinoic acid induces COUP-TFII-
dependent transactivation and enhances coactivator bind-
ing [36]. These findings encourage us to screen and iden-
tify the specific COUP-TFII antagonists or inhibitors and
examine its effects in pre-clinical cancer models, which
can be potentially used for cancer intervention.
Although tremendous progress have been made regard-
ing to the roles of COUP-TFII in tumorigenesis, there are
many questions that remain to be addressed. Given the
fact that COUP-TFII is generally important for cellular
differentiation and lineage determination, it leaves open
the possibility that COUP-TFII might be involved in can-
cer stem cells homeostasis. Specifically, it is interesting
to address whether COUP-TFII is involved in the re-
programming of terminally differentiated cells into dedif-
ferentiated cancer stem cells or tumor progenitor cells.
Also, what is role of COUP-TFII in drug resistance? For
instance, since COUP-TFII was reported to interact with
androgen receptor (AR) to modulate its transcription ac-
tivity in prostate cancer cells [37], COUP-TFII might be
involved in the development of castration resistance pros-
tate cancer (CRPC). Finally, having established the onco-
genic role of COUP-TFII in prostate cancer, we need to
address the precise roles of COUP-TFII in other cancertypes. Based on patient data mentioned above, we believe
COUP-TFII exerts its function in a context and cancer cell
type dependent manner.
Except for the pathological roles of COUP-TFII, the de-
tailed mechanism for COUP-TFII action remains to be
further elucidated. First, what is the underlying mechan-
ism for COUP-TFII driving tumor cells to become more
metastatic? COUP-TFII might be involved in epithelial-
mesenchymal transition to facilitate tumor cells metastasis
and subsequently colonization in the distant organs. As a
transcription factor, it is unclear how COUP-TFII activates
the expression of some target genes, while at the same
time represses the expression of other sets of genes. Fur-
ther identification of the COUP-TFII interactome and
transcriptome will help to address this complicated issue.
In addition, as a nuclear protein, how does COUP-TFI re-
spond to extracellular insults to coordinate its function?
For instance,
which oncogenic insults are responsible for the upregula-
tion of COUP-TFII expression in prostate cancer cells?
Addressing the questions raised above will help us under-
stand further the signaling crosstalk mediated by COUP-
TFII during tumorigenesis. In summary, future studies, in-
cluding genome-wide approaches and detailed analysis of
COUP-TFII-dependent genetic programs will be essential
to comprehensively understand the roles of COUP-TFII in
tumor progression and metastasis.
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